Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Decreases By 38.6%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 9,400 shares, a decline of 38.6% from the August 31st total of 15,300 shares. Based on an average daily trading volume, of 2,360,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.7% of the shares of the stock are short sold.

Salarius Pharmaceuticals Stock Performance

SLRX remained flat at $1.44 during midday trading on Friday. The company’s stock had a trading volume of 31,138 shares, compared to its average volume of 829,901. The stock has a market capitalization of $856,695.00, a P/E ratio of -0.07 and a beta of 0.95. Salarius Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $7.60. The company’s 50-day moving average is $1.94 and its two-hundred day moving average is $2.99.

Salarius Pharmaceuticals (NASDAQ:SLRX) last posted its quarterly earnings results on Friday, August 9th. The company reported ($2.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($53.60) by $51.23. On average, research analysts expect that Salarius Pharmaceuticals will post -214.4 EPS for the current year.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.